When it was approved in 2003 as the first new laser in five years, the FDA granted ALLEGRETTO WAVE® the widest approval range ever initially given to a new laser for both myopic and hyperopic vision correction. Since then, the results have been astoundingly positive. ALLEGRETTO WAVE® has been proven to provide superior clinical results, as shown by the following statistics:

• At one year after treatment, more than 93% of patients said they saw at least as well or better than they had with glasses or contacts before treatment.
• More than 98% of patients achieved 20/40 vision one year after treatment; 20/40 is the level of visual acuity required to pass most driving tests.
• Nearly 60% of near-sighted patients achieved 20/16 vision after one year of treatment.
• Both near- and far-sighted patients reported an improvement in their reaction to bright lights and night driving glare after ALLEGRETTO WAVE® treatments. In addition, near-sighted patients reported an improvement in sensitivity to light.
• Predictable results are the norm for the ALLEGRETTO WAVE®. More than 90% of patients achieve refraction within 1 diopter of their target correction.